PD-L1 Monoclonal Antibody-Conjugated PEGylated Nanoparticles forBrain Cancer Immuno-Chemotherapy via Activation of STING Pathway

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Immunotherapy for cancer is regarded as an alternative to conventional chemotherapy. Novel approach to cancer treatment called STING-targeted activation is being studied in great detail. Thus, self-assembly PEGylated coated, ovalbumin (OVA), loaded PC7A polymer, conjugated with PD-L1 (programmed death-ligand-1) monoclonal antibody (mAb) [OVA-PEG-PC7-A-mAb] was prepared by emulsion solvent evaporation. Further, physicochemical characterization and release kinetic was performed. Further, PD-L1-mAb-conjugated NPs, investigated for cellular-uptake, cytotoxic-effects, and apoptosis in PD-L1-expressing human GC cell lines, and in vivo pharmacokinetic and bio-distribution study was performed. The investigation of structure and interaction activity of PD-L1-OVA-PEG-PC7-A-mAb NPs involved the utilization of X-ray photoelectron spectroscopy, which confirmed the presence of PD-L1-mAbs on the surface of NPs. Cellular-uptake examination demonstrated that NPs conjugated with antibodies exhibited expressively enhanced levels of cellular-uptake. NPs demonstrated by in-vitro cytotoxicity experiment on 6-glioma cell lines proof the targeting efficiency. Ova-PEG-PC7-A-mAb, NPs showed greatest STING pathway activation, confirmed by higher release of IFN-𝛽) and IL-6. In-vivo study biodistribution and pharmacokinetic confirm the specific targeting in brain region. Our findings, presented here, demonstrate that biological immune-therapeutic potential of OVA-PEG-PC7-A-mAb NPs by activation mechanism of the STING pathway using PD-L1 mAbs in brain cancer therapy.

Article activity feed